drugset / Trial / NCT05428436
A Study in Healthy People to Compare 2 Different Formulations of BI 1015550 Taken With or Without Food
RandomizedCrossoverOpen-labelTreatment
Summary
The main objective of this trial is to investigate the relative bioavailability of BI 1015550 intended Commercial Formulation (iCF) compared with Trial Formulation 2 (TF2) and the effect of food on the pharmacokinetics of BI 1015550 iCF following oral administration.
Timeline
- Start
- 2022-08-15
- Primary completion
- 2022-09-30
- Completion
- 2022-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nerandomilast | Small molecule | 18 mg | Oral |
Indications
No indication recorded.